XGXuezhong Gu

Xuezhong Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xuezhong Gu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Haixi Zhang

    Department of Hematology, The First People’s Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Yunnan Province Clinical Center for Hematologic Disease, Kunming, 650032, China

    2 shared publications
  • Jie Zhao

    Department of Hematology, The First People’s Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Yunnan Province Clinical Center for Hematologic Disease, Kunming, 650032, China

    2 shared publications
  • Arunachalam Chinnathambi

    King Saud University

    1 shared publication
  • Duan Hua Nan

    Yunnan Provincial Clinical Medical Center for Digestive Diseases/Gastroenterology, The First People's Hospital of Yunnan Province

    1 shared publication
  • Fan Li

    Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Hematol, Kunming, Yunnan, Peoples R China

    1 shared publication
  • Fen Mm Li

    Department of Hematology, The First People’s Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Yunnan Province Clinical Center for Hematologic Disease, Kunming, 650032 Yunnan, China

    1 shared publication

Latest Publications

  • Open Access

    Identification of iron metabolism-related key genes and exploration of their potential mechanisms in hemophagocytic lymphohistiocytosis based on transcriptome sequencing

    by Li Fen, Duan Hua Nan, Yu Lin Na, Zhao Jie, Gu Xue Zhong

    Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory disorder caused by excessive immune activation. This exploratory study aimed to systematically identify potential diagnostic key genes linked to iron metabolism during HLH progression using comprehensive bioinformatics analysis and explore the underlying mechanisms. Methods: Thirty peripheral blood mononuclear cell (PBMC) samples—15 from patients with HLH and 15 controls—were analyzed through mRNA sequencing. Total RNA was extracted from these samples. First, the overlap between differentially expressed genes (DEGs) and iron metabolism-related genes (FeRGs) was identified to select candidate genes. Key genes were then derived using the Boruta method and least absolute shrinkage and selection operator (LASSO) regression analysis. Further investigations, including correlation, functional, and enrichment analyses, as well as immune infiltration and drug prediction, were performed to explore the molecular mechanisms. Finally, reverse transcription quantitative PCR (RT-qPCR) was used to validate the expression levels of the key genes in clinical specimens. Results: The intersection of 464 DEGs and 520 FeRGs identified 10 candidate genes. Machine learning analysis identified ALOX15, CAT, HBZ, MT2A, and CYGB as HLH key genes. A significant positive correlation was observed between ALOX15 and HBZ, while ALOX15 showed a notable negative correlation with CYGB and MT2A (|correlation coefficient (r)| > 0.3, p < 0.05). These key genes were functionally associated with antioxidant activity, toxic substance response, and inorganic compound detoxification, primarily involved in oxidative phosphorylation and Huntington’s disease-related pathways. Notably, ALOX15 and CAT were significantly correlated with activated dendritic cells and CD4 memory T cells. Drug prediction revealed 15 compounds targeting ALOX15, MT2A, and CAT. Expression of ALOX15, CAT, and HBZ was down-regulated, while MT2A and CYGB were up-regulated in the HLH group, consistent with differential expression trends. Conclusion: This study identified five validated key genes—ALOX15, CAT, HBZ, MT2A, and CYGB—offering new insights into HLH pathogenesis and potential therapeutic targets.


  • Open Access

    Pyoderma gangrenosum complicated with hematological malignancies: Two case reports

    by Fen Mm Li, Jie Mm Zhao, Huanan Mm Duan, Haixi Mm Zhang, Lin Mm Zhang, Liangyun Zhao, Yan Bs Wen, Xuezhong Mm Gu

    Introduction: Pyoderma gangrenosum (PG) is a rare noninfectious neutrophilic skin disease. The diagnosis of PG is mainly based on clinical manifestations. Therefore, the clinical features of PG are important for confirming the diagnosis of this disease. Herein, the clinical data of 2 young males with PG complicated with hematological malignancies were reported, and the literature were reviewed. Case presentation: The first case was a 22-year-old male who was admitted due to a systemic rash, headache, and fever. Physical examination showed black scabs on the skins of the extremities, trunk, scalp, and face. Biopsy of the skin lesion showed epidermal edema, spongy formation, neutrophil infiltration, acute and chronic inflammatory cell infiltration in the dermis, showing purulent inflammation with epidermal erosion. The bone marrow biopsy showed obviously active proliferation of nucleated cells, granulocytes at various stages, abnormal morphological neutrophils, and occasionally observed young red blood cells. The diagnosis of PG and chronic myelomonocytic leukemia (CMML-0) was made. The second case was a 28-year-old male who presented a swollen, painful right calf following injury and then developed ulcers on skin and soft tissues. Bone marrow biopsy showed obviously active nucleated cell proliferation, suggesting a myeloid tumor. He was also diagnosed with PG and hematological malignancies. They both received hormone and antiinfection therapy. After treatment, their body temperature, infection, and skin lesions were improved. However, both of them were readmitted and had a poor prognosis. Conclusions: PG may be associated with hematological malignancies. For patients with typical skin lesions and obvious abnormal blood routines, it is necessary to investigate the possibility of PG with hematological malignancies.


  • Open Access

    Identification of TNFRSF1A as a novel regulator of carfilzomib resistance in multiple myeloma

    by Jie Zhao, Xuantao Yang, Haixi Zhang, Xuezhong Gu

    Multiple myeloma (MM) is a hematological tumor with high mortality and recurrence rate. Carfilzomib is a new-generation proteasome inhibitor that is used as the first-line therapy for MM. However, the development of drug resistance is a pervasive obstacle to treating MM. Therefore, elucidating the drug resistance mechanisms is conducive to the formulation of novel therapeutic therapies. To elucidate the mechanisms of carfilzomib resistance, we retrieved the GSE78069 microarray dataset containing carfilzomib-resistant LP-1 MM cells and parental MM cells. Differential gene expression analyses revealed major alterations in the major histocompatibility complex (MHC) and cell adhesion molecules. The upregulation of the tumor necrosis factor (TNF) receptor superfamily member 1A (TNFRSF1A) gene was accompanied by the downregulation of MHC genes and cell adhesion molecules. Furthermore, to investigate the roles of these genes, we established a carfilzomib-resistant cell model and observed that carfilzomib resistance induced TNFRSF1A overexpression and TNFRSF1A silencing reversed carfilzomib resistance and reactivated the expression of cell adhesion molecules. Furthermore, TNFRSF1A silencing suppressed the tumorigenesis of MM cells in immunocompetent mice, indicating that TNFRSF1A may lead to carfilzomib resistance by dampening antitumor immunity. Furthermore, our results indicated that TNFRSF1A overexpression conferred carfilzomib resistance in MM cells and suppressed the expression of MHC genes and cell adhesion molecules. The suppression of MHC genes and cell adhesion molecules may impair the interaction between immune cells and cancer cells to impair antitumor immunity. Future studies are warranted to further investigate the signaling pathway underlying the regulatory role of TNFRSF1A in MM cells.


  • Anti‐cancer potential of selenium‐chitosan‐polyethylene glycol‐carvacrol nanocomposites in multiple myeloma U266 cells

    by Haixi Zhang, Jie Zhao, Arunachalam Chinnathambi, Velmurugan Meganathan, Xuezhong Gu

    Multiple myeloma (MM) is an incurable cancer that is characterized by malignant plasma cell proliferation. Approximately 10% of all blood cancers are MM, and there is no standard curative therapy. In this work, we intended to synthesize, characterize, and assess the anticancer effects of selenium/chitosan/polyethylene glycol–carvacrol nanocomposites (SCP‐Car‐NCs) on MM U266 cells in vitro. Various characterization techniques were used to characterize the synthesized SCP‐Car‐NCs. Several in vitro free radical scavenging experiments were conducted to test the ability of synthesized SCP‐Car‐NCs to scavenge the different free radicals. The cytotoxicity of SCP‐Car‐NCs was assessed on Vero and U266 cells using the 3‐[4,5‐dimethylthiazol‐2‐yl]‐2,5 diphenyl tetrazolium bromide (MTT) assay. By using various fluorescence staining techniques, the amount of reactive oxygen species (ROS) generation, MMP, and apoptosis were measured. Using commercial test kits, the levels of oxidative stress and apoptotic biomarkers in control and treated U266 cells were assessed. The highest peak in the UV spectral analysis was found to be at 271 nm, demonstrating the development of SCP‐Car‐NCs. Fourier transform infrared analysis showed that the synthesized SCP‐Car‐NCs contained a variety of stretching and bonding. The X‐ray diffraction study confirmed the crystallinity of SCP‐Car‐NCs. The dynamic light scattering analysis showed that the SCP‐Car‐NCs had an average size of 171 nm. The different free radicals, such as the 2,2‐diphenyl‐1‐picrylhydrazyl, hydroxyl, and peroxyl radicals, were significantly scavenged by the SCP‐Car‐NCs. According to the MTT assay results, the SCP‐Car‐NCs decreased the viability of U266 cells while having no impact on the proliferation of Vero cells. The SCP‐Car‐NCs significantly boosted ROS production, decreased the MMP level, and promoted apoptosis, as evidenced by the fluorescence staining experiments. In U266 cells treated with SCP‐Car‐NCs, the level of thiobarbituric acid reactive substances increased while superoxide dismutases and glutathione levels were reduced. In the SCP‐Car‐NCs treated U266 cells, it was found that the Bax, caspase‐3, and −9 activities had increased while the Bcl‐2 level had decreased. In conclusion, our findings show that SCP‐Car‐NCs treatment reduced the viability and increased apoptosis in the U266 cells, providing a new insight on SCP‐Car‐NCs' potential for usage in the future to treat MM.


    • 1 April 2023
      • Vol. 29  (3) , 266-270

    Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report

    by Yating Lin, Jun He, Fan Li, Xuezhong Gu

    Background . Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by bone marrow dysplasia, ineffective hematopoiesis, and cytopenias. Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients have a high risk of secondary MDS or acute myeloid leukemia (AML) compared to healthy persons, and chemotherapy or transplantation may result in secondary treatment-related MDS. Methods . A patient was diagnosed with both MDS and MGUS, which was treated using thalidomide, dexamethasone, and danazol. A follow-up blood test was conducted to determine leukocyte and hemoglobin levels. Results . Immunoprotein electrophoresis showed M protein peak with IgA+ kappa components. Nuclear cells proliferated actively in bone marrow aspirates. Bone marrow analysis suggested a myelodysplastic syndrome with myeloblastoma (MDS-RS) and a new plasmacytoma. The immunophenotype was shown as follows: R5 cells (red) are about 15.5%. Among the CD38+CD45 cells, about 95.9% of cKappa cells and 1.7% of cLambda cells are considered as plasmacytoma. Gene detection showed that the patient carried 14 gene mutations, and karyotype analysis showed that they had normal male chromosome structure. The patient was diagnosed as MDS and MGUS, and finally discharged after treatment with thalidomide (75 mg daily), dexamethasone (3 mg daily), and danazol (200 mg twice daily). Within 1 year, the disease has stabilized. Conclusion . The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease

  • Open Access

    Characterization of microRNA expression profiles by deep sequencing of small RNA libraries in leukemia patients from Naxi ethnic

    by Zhenglei Shen, Xuezhong Gu, Wenwen Mao, Honghua Cao, Rui Zhang, Yeying Zhou, Kunmei Liu, Lilan Wang, Zhe Zhang, Liefen Yin

    Background: Leukemia is a hematological malignancy characterized by the proliferation of early lymphoid precursors that replaces normal hematopoietic cells of the bone marrow. Nakhi (Naxi) ethnic minorities considered to be an area of low incidence. MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate the expression of other genes in various biological processes. The purpose of this work is to study the molecular mechanism of miRNAs in the leukemia from Naxi. Methods: Six leukemia patients (case 2 to case 7) and one healthy person (case 1) from Nakhi (Naxi) ethnic minorities were recruited. Total RNA was extracted from these samples and small RNA deep sequencing was performed. Results: A list of miRNAs (1,392 known and candidate 125 novels) expressed in leukocytes were identified, and many differentially regulated targets involved in several cellular pathways, such as cancer, Rap1 signaling pathway, Ras signaling pathway, and endocytosis. Additionally, quantitative real time-polymerase chain reaction (qRT-PCR) results show that hsa-miR-181b-5p, hsa-miR-181a-3p, hsa-miR-181a-5p, and hsa-miR-342-3p has different expression patterns in different cancer cells, hsa-miR-450a-5p, and hsa-miR-1255a were dysregulated in all leukemia cells. Conclusions: Several abnormal expressed miRNAs in leukemia patients were identified, the correlation of miRNAs dysregulation and leukemia biology demonstrates that specific miRNA can be potential therapeutic target.